RIZOXAN (Capsules)

 

TRADE NAME

Rizoxan

(Dry milk thistle fruit extract, Dry Curcuma zanthorriza rhizome extract, Dry chelidonium herb and root extract)        

COMPOSITION

Each capsule contains:

Dry milk thistle fruit extract                                                       140 mg

Dry Curcuma zanthorriza rhizome extract                              25 mg

Dry chelidonium herb and root extract                                  80 mg

 

PHARMACOLOGICAL PROPERTIES

PHARMACODYNAMICS

Rizoxan is a complex herbal medication and its effect depends on the collective function of its components. Silibinin is one of the components of milk thistle. It has hepatoprotective and antioxidant properties. It interacts with hepatocyte membranes and stabilizes them, and as a result prevents transaminase deficit. It binds free radicals, inhibits lipid peroxidation, prevents destruction of cell structure (consequently malondialdehyde formation and oxygen consumption are reduced). It prevents penetration of various hepatotoxic substances into cells. By stimulating RNK-polymerase it increases biosynthesis of proteins and phospholipids and accelerates regeneration of damaged hepatocytes. In alcoholic hepatitis it blocks the production of acetaldehyde and binds free radicals, it protects glutathione reserves, which facilitates detoxification in hepatocytes.

Alcaloin chelidonin, component of chelidonium, has antispasmodic, analgesic and cholagogue effect.

Curcumin is an active component of turmeric. It has cholagogue effect (both choleretic and cholekinetic) and anti-inflammatory properties. It decreases biliary cholesterol saturation, it shows bactericidal and bacteriostatic activity towards Staphylococcus aureus, Salmonella spp. and Mycobacterium tuberculosis.

 

PHARMACOKINETICS

The therapeutic effect of Rizoxan depends on collective function of its components. Therefore, it is impossible to conduct kinetic research.

 

THERAPEUTIC INDICATIONS 

As part of complex therapy in treatment of:

•         toxic liver dysfunction (including alcoholic and pharmacological)
•         acute and severe hepatitis of any etiology (as part of supportive therapy)
•         liver cirrhosis (as part of supportive therapy)
•         gallbladder and bile duct diseases such as acute cholecystitis, cholangitis, gallbladder and biliary dyskinesia
•         pain syndrome (spastic type) associated with other gastrointestinal diseases
•         postcholecystectomy syndrome
•         bile duct dilatation and varicose veins in the gastrointestinal tract

-        dyspepsia.

 

CONTRADICTIONS

Hypersensitivity to any components of the medication, biliary tract blockage.

 

SIDE EFFECTS

Allergic reactions to the components of the medication are rarely possible. In other cases mild weakness, sometimes discomfort in epigastric region. During prolonged administration dyspeptic disorders may sometimes occur.

 

DOSAGE AND ADMINISTRATION 

Rizoxan should be taken orally before food and washed down with small amount of liquid. 

At the beginning of the treatment the dose is 2 capsules 3 times a day (for no longer than 2 weeks) and after that 1 capsule 3 times a day for 1-3 months.

Treatment can be repeated after 1-3 months.

PACKAGING

Hard gelatine capsules.

15 capsules are in a blister.

2 blisters together with a leaflet are in a carton box.